Welcome
Biothera's Pharmaceutical Group is developing drugs that enhance innate immune responses to a variety of diseases. Cancer is our primary focus. Our keystone technology is a novel way to induce immune cells not normally engaged in the fight against cancer to recognize and kill tumor cells. Biothera's technology platform is synergistic with the vast majority of monoclonal antibodies and cancer vaccines approved for clinical use or in development, representing hundreds of potentially new cancer treatments.
Video
This three-minute animation illustrates how Biothera's Imprime PGG® works inside the body to prime innate immune cells to recognize and kill a wide range of pathogens and cancer cells.
Watch Now
Research
Biothera’s Imprime PGG enhances the effectiveness of Avastin® (bevacizumab), a monoclonal antibody approved for the treatment of metastatic colorectal, breast and non-small cell lung cancer.
| Click here for the Clinical Cancer Research article abstract |